TTK Healthcare Ltd. Stock Falls to 52-Week Low of Rs.916

Stock Price Movement and Market Context

On 24 Feb 2026, TTK Healthcare’s share price touched Rs.916, its lowest level in the past year, representing a sharp contrast to its 52-week high of Rs.1,402. Despite outperforming its sector by 0.51% on the day, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure.

The broader market environment has also been challenging. The Sensex opened 242.12 points lower and closed down 495.76 points at 82,556.78, a decline of 0.89%. Although the Sensex remains within 4.36% of its 52-week high of 86,159.02, it is trading below its 50-day moving average, indicating some near-term weakness. This market backdrop compounds the difficulties faced by TTK Healthcare.

Financial Performance and Growth Trends

TTK Healthcare’s long-term growth trajectory has been modest. Over the last five years, net sales have increased at an annual rate of 6.99%, while operating profit has grown at 15.42%. These figures suggest a steady but unspectacular expansion, which has not translated into strong stock performance. The company’s one-year stock return of -24.41% starkly contrasts with the Sensex’s positive 10.88% return over the same period.

Recent quarterly results have been largely flat, with no significant improvement in key metrics. Cash and cash equivalents at the half-year mark stood at Rs.600.89 crores, the lowest level recorded in recent periods. Additionally, the debtors turnover ratio has declined to 7.40 times, indicating slower collection efficiency. Non-operating income accounted for 80.43% of profit before tax in the latest quarter, highlighting a reliance on income sources outside core operations.

Market Perception and Shareholding Patterns

Despite its sizeable market presence, TTK Healthcare commands only a minimal stake from domestic mutual funds, which hold a mere 0.01% of the company. Given that mutual funds typically conduct thorough research and due diligence, this limited exposure may reflect a cautious stance towards the stock’s valuation or business prospects.

The company’s Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold on 21 Jul 2025. This rating reflects concerns about the company’s growth prospects and financial metrics relative to its peers within the diversified sector.

Comparative Performance and Valuation Metrics

TTK Healthcare’s underperformance extends beyond the last year. The stock has lagged the BSE500 index over the past three years, one year, and three months, underscoring persistent challenges in delivering shareholder returns. Its price-to-book value ratio is 1.2, indicating a premium valuation compared to peer averages, despite subdued growth.

The company’s return on equity (ROE) is 6.5%, a moderate figure that suggests limited efficiency in generating profits from shareholders’ equity. The PEG ratio, which relates price-to-earnings to earnings growth, is elevated at 7.9, signalling that the stock’s price may not be fully justified by its earnings growth rate, which rose by only 2.4% over the past year.

Balance Sheet and Debt Profile

TTK Healthcare maintains a conservative capital structure, with an average debt-to-equity ratio of zero. This low leverage reduces financial risk but has not translated into stronger market performance. The company’s cash position, while diminished, remains substantial, providing some liquidity cushion.

Summary of Key Metrics

To summarise, TTK Healthcare Ltd. is currently trading at Rs.916, its lowest point in the last 52 weeks, down approximately 34.6% from its peak of Rs.1,402. The stock’s Mojo Grade downgrade to Sell and a score of 37.0 reflect concerns about its growth and profitability. While the company’s conservative debt profile and reasonable ROE provide some stability, the limited earnings growth and reliance on non-operating income weigh on its valuation.

The stock’s underperformance relative to the Sensex and BSE500 indices over multiple time frames highlights the challenges faced by TTK Healthcare in delivering competitive returns. Its premium valuation metrics relative to peers further complicate the investment case.

Overall, the new 52-week low price underscores the market’s cautious stance towards TTK Healthcare amid subdued financial results and broader market pressures.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today